ICARE Social Media Post January 2023

New ASCO Germline Testing in Patients With Breast Cancer Guidelines

The American Society of Clinical Oncology (ASCO) just released new guidelines for germline testing in patients with breast cancer, which include the following:
🧬 BRCA1/2 testing should be offered to ALL patients diagnosed with breast cancer at or below age 65
🧬 Testing for other hereditary cancer genes should also be offered based on personal and family history
🧬 Testing for other HIGH penetrance genes (such as a PALB2, TP53, PTEN, STK11, and CDH1) could inform medical care; thus, testing for these genes should be offered to appropriate patients
🧬 Testing for MODERATE penetrance genes (such as ATM, CHEK2, RAD51C, RAD51D, and BARD1) currently offer no treatment benefits for breast cancer patients, but may inform risks of second primary cancers or family risk; thus, testing may be offered to appropriate patients

Learn more by reading the full article at: https://ascopubs.org/doi/10.1200/JCO.23.02225

Permanent link to this article: https://inheritedcancer.net/post10524/